A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy
This study is testing and comparing two different combinations of cancer medications to see which one works better and is safer for advanced breast cancer. It focuses on patients whose cancer has a specific genetic change called PIK3CA and has continued to grow after previous treatments.
You may be able to join if you have advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA gene mutation that got worse after standard hormone therapy. Participants must be able to swallow pills and not have certain conditions like type 2 diabetes needing medication.
Participants will be randomly assigned to receive one of two medication combinations, which include targeted cancer drugs and hormone therapy pills. You will be closely monitored by the study team throughout the treatment for safety and effectiveness.
The study has locations in places like Greenbrae, Los Alamitos, and Los Angeles, California. While enrollment for the main study is currently complete, status updates can help you check for any new openings.
- 1Compares two medication combinations for advanced breast cancer
- 2Requires a specific genetic mutation called PIK3CA in the cancer cells
- 3Involves taking study treatments and receiving regular check-ups
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.